plantation for cystic fibrosis. Proc Am Thorac Soc 2009;6:619–633 [13] Bech B, Pressler T, Iversen M, Carlsen J, Milman N, Eliasen K, Perko M, Arendrup H. Long-term outcome of lung transplantation for cystic fibrosis—Danish results. Eur J Cardiothorac Surg 2004;26:1180–1186 [14] Algar FJ, Cano JR, Moreno P, Espinosa D, Cerezo F, Alvarez A, Baamonde C, Santos F, Vaquero JM, Salvatierra A. Result...

BACKGROUND Lung transplantation is an accepted therapeutic option for patients with end stage pulmonary sarcoidosis. However, the medium term outcome of transplantation in this patient group is unknown. METHODS This study was performed to evaluate our experience with lung transplantation for end stage pulmonary sarcoidosis. Between July 1988 and July 1997 12 patients (nine men) underwent lung...

BACKGROUND Chronic obstructive pulmonary disease (COPD) is the leading indication for lung transplantation; however, these patients rarely gain priority on the waiting list until very late. The clinical status can be improved by surgical lung volume reduction; this procedure, although carries significant morbidity, has been repeatedly advocated as a bridge. Recently, bronchoscopic lung volume r...

The aim of our study was to characterize the time course and magnitude of the changes in lung function in the first year after cardiac transplantation. Resting pulmonary function tests (spirometry, lung volumes and transfer factor) were performed in 14 patients prior to and at 1, 3 and 12 months after surgery. Resting central haemodynamics were also measured serially in the first year post-tran...

A lthough medical management has considerably improved, cystic fibrosis (CF) remains a major cause of mortality from suppurative lung disease, in children and young adults. Lung transplantation is currently the only available efficient treatment of the life-limiting aspects of the condition to achieve improved quality of life and long-term survival in these patients, who stand to benefit more f...

Lung transplantation has been available as a therapeutic option for patients with end-stage cystic fibrosis lung disease for over 15 years, but the outcome following transplantation remains poor, and the supply of organs limited. For this reason some children opt to continue with medical treatment followed by terminal care rather than undergo transplantation. This article summarizes the current...

Lung transplantation is a well-accepted life-saving treatment for end-stage lung diseases. However, the short-term and long-term success of lung transplantation is hindered by multiple factors such as the shortage of organ donors, primary graft dysfunction, life-long immunosuppression and chronic graft dysfunction. Gene transfection presents a potential molecular therapeutic solution to these p...

Lung transplantation has become an accepted treatment modality for end stage lung disease. Traditionally, immunosuppressive maintenance therapy consists of cyclosporin, azathioprine, and prednisolone in kidney and liver transplantation as well as in lung transplantation. Despite the use of these drugs, acute rejection occurs frequently, especially in the first weeks and months after lung transp...

PurposePatients with end-stage lung disease and cardiac dysfunction may be considered for dual heart transplantation. End-stage can cause increased pulmonary vascular resistance (PVR) and/or right ventricular (RV) that leads to left (LV) pseudo cardiomyopathy. Lung transplantation corrects the underlying pathology allow recovery of LV function. We aim identify patients who recover function foll...

Coronary artery disease is occasionally encountered in lung transplant recipients and is a risk factor for perioperative complications and poor survival. Besides combined heart–lung transplantation, various techniques of myocardial revascularization can be performed before, or at the time of lung transplantation. We report herein a patient with end-stage bronchoemphysema and two-vessel coronary...